On
this World Sarcopenia Day, observed annually on 4th July, Pharmed Limited, a
leading pharmaceutical company based in Bengaluru, India, has set a new
benchmark in healthcare, earning a place in the Asia Book of Records. As
India's elderly population grows at an unprecedented pace, the record
recognises an extraordinary commitment from 10,451 doctors to screen and manage
Sarcopenia — the progressive, age-related loss of muscle mass and strength — in
their elderly, chronic disease, and patients post-surgery .
The
record-breaking pledge marks a significant milestone in the company's efforts
to promote healthy ageing and improve quality of life nationwide. The award was
presented at Pharmed's corporate office in Bengaluru, with Dr Manohar KN, a
renowned Consultant Physician and Diabetologist from Bangalore, attending as
the guest of honour, alongside the Asia Book of Records team and members of
Pharmed.
On
the importance of early sarcopenia screening, Dr Manohar said, "Sarcopenia
is one of the most under-recognised yet clinically significant conditions
affecting adults, particularly the elderly. While its impact on ageing,
frailty, falls, fractures, and loss of independence is well established, its
pivotal role in metabolic disease is only now coming into sharp focus. Skeletal
muscle is increasingly recognised as an endocrine organ, making muscle health
central to metabolic health. The future of metabolic medicine will extend
beyond controlling blood sugar or body weight to preserving and restoring
muscle mass and strength. Emerging therapies that target muscle health are
likely to transform the management of diabetes, obesity, and other metabolic
disorders."
"This
record commitment from 10,451 doctors is not just a number; it represents a
collective commitment to the health and independence of our ageing population.
At Pharmed, we believe in driving meaningful change in healthcare. This
initiative reflects our dedication to addressing critical, under-recognised
health issues like sarcopenia and our continued efforts to support muscle
health, healthy ageing, and better recovery — working hand in hand with
healthcare professionals to make a real difference,"
added Kashmiri Lal Kapoor, Director of Operations at Pharmed.
India
is home to one of the world's fastest-growing elderly populations, and with
this demographic shift comes a rising burden of sarcopenia. According to the
first Indian consensus on sarcopenia, published in 2025, the prevalence of
primary sarcopenia ranges from 14.2% to 39.2% in adults — meaning roughly four
out of 10 adults, and three out of 100 young adults, are affected. Ageing,
combined with India's high prevalence of diabetes, a sedentary lifestyle,
chronic inflammation, and poor nutritional status, places millions at risk of
significant muscle loss, which can lead to falls, prolonged hospital stays,
poorer surgical outcomes, and reduced quality of life. With the consensus
recommending screening for all patients with comorbidities, monitoring every
three to six months depending on severity, and resistance training combined
with oral nutritional supplementation to prevent and manage the condition,
early intervention has become an urgent public health priority.
Pharmed
is leading the way in India — supporting effective sarcopenia management
through evidence-based, quality nutritional supplementation and patient
education initiatives such as its Care for Muscles programme, while
collaborating with doctors to promote the right screening techniques,
sarcopenia awareness, exercise modules, and more. This recognition marks an
important milestone in its mission. By securing commitments from so many
doctors, Pharmed aims to make muscle health screening a routine part of care
for elderly, diabetic, and post-surgical patients, and to create a significant
impact on healthy ageing across the country.